Enovis (ENOV) Q2 2026 earnings review
Solid Reconstructive Execution Drives Q2, but H2 Macro Caution Lingers
Enovis delivered a stable second quarter, posting 5% organic revenue growth and driving Adjusted EBITDA margins up to 17.9%. The Reconstructive segment continues to act as the primary growth engine, accelerating to 6.3% organic growth on the back of new product introductions. Despite the top-line and margin momentum, management opted to reaffirm—rather than raise—full-year guidance. This signals a defensive posture heading into the second half, likely anticipating continued supply chain, freight, and geopolitical headwinds that were heavily cited in recent quarters.
🐂 Bull Case
The Reconstructive division is structurally outperforming the market, accelerating to 6.3% organic growth driven by strong US momentum and the rollout of the Arvis Gen 2 surgical guidance system.
Following SEC-mandated reporting changes that stripped out inventory step-up adjustments, Adjusted EBITDA still expanded 170 basis points year-over-year to 17.9%, proving the underlying EGX business system is driving real operating leverage.
🐻 Bear Case
International Prevention & Recovery organic growth flatlined at 0.0% in Q2, indicating that global market volatility and supply chain friction are materially impacting the segment's ability to drive volume.
Refusing to raise FY26 guidance after a strong H1 indicates management expects H2 macro headwinds—specifically freight inflation and international disruptions—to offset operational gains.
⚖️ Verdict: ⚪
Neutral/Bullish. Enovis is fundamentally reshaping its portfolio to focus on high-margin, high-growth Reconstructive assets. The commercial execution is there, but holding guidance flat implies they expect a tough macro environment to consume their H2 upside.
Key Themes
Reconstructive Innovation Driving Share Gains
The Reconstructive segment continues its role as Enovis's primary growth engine. Organic growth in Recon is accelerating, moving from 5.5% in 26Q1 to 6.3% in 26Q2. The commercial launch of the Arvis Gen 2 surgical guidance system and the Nebula hip system are acting as critical competitive wedges, opening up accounts and driving implant pull-through in both US (+6.4% organic) and International (+6.2% organic) markets.
ASC Migration and the Continuum of Care
Macro picture: Enovis is successfully leaning into the structural shift of orthopedic procedures to Ambulatory Surgery Centers (ASCs). Management's strategy of utilizing portable, capital-light enabling technology (like Arvis) as a Trojan horse to secure ASC contracts is yielding durable growth, capturing market share without the heavy capital expenditure requirements that hinder legacy robotic systems.
The Dr. Comfort Divestiture Drag
While management touts a reshaped portfolio, the optics of the Prevention & Recovery (P&R) segment remain messy. U.S. Other P&R reported a severe 15.8% revenue decline, despite management claiming 4.6% organic growth. This divergence highlights the ongoing nominal revenue penalty from the Dr. Comfort divestiture, forcing the Reconstructive segment to carry the entire company's reported growth metrics.
International P&R Grind to a Halt
While Reconstructive executed well overseas, International P&R is decelerating rapidly. Organic growth flatlined entirely at 0.0% in Q2, down from 0.9% in Q1. If international macro volatility (previously cited strikes and freight disruptions) continues, P&R will become a significant anchor on total company performance in H2.
Maintaining Guidance Signals Macro Vulnerability
Enovis delivered a beat on Q2 expectations but maintained its FY26 guidance. This conservative posture suggests management views the dynamic macroeconomic environment—specifically Middle East friction, supply chain inflation, and persistent tariff pressures—as a genuine threat that will offset H2 operational outperformance.
Other KPIs
Accelerating. Enovis expanded Adjusted EBITDA margins to 17.9%, up from a restated 16.2% in 25Q2. This 170-basis-point expansion proves the EGX business system is successfully driving manufacturing and supply chain productivity, overcoming lingering tariff and freight inflation.
Stable and structurally higher. Up from 59.3% in the prior year period. The improvement is heavily tied to the portfolio mix shift, shedding lower-margin P&R legacy assets (like Dr. Comfort) and growing higher-margin Reconstructive implants.
Guidance
Stable. The company maintained its full-year revenue outlook, which implies 4-6% organic growth. Given H1 organic growth came in at 4.1%, the guidance implies a slight acceleration in the back half of the year to hit the midpoint.
Stable. The midpoint of $3.625 represents a healthy ~10% acceleration over FY25's $3.30. Holding this range despite the Q2 beat implies a conservative approach to H2 operating expenses or anticipated macro headwinds.
Stable. The company continues to target 25%+ FCF conversion. Considering the heavy capital expenditures historically required to seed Reconstructive instrumentation, meeting this target will require disciplined working capital management in H2.
Key Questions
International P&R Weakness
International P&R organic growth dropped to 0.0% this quarter. Is this a result of specific regional market disruptions, or are there structural competitive issues in the international bracing and support markets?
Guidance Conservatism
Despite strong execution and a 170 bps expansion in Adjusted EBITDA margins in Q2, full-year guidance was merely reaffirmed. What specific macroeconomic or supply chain headwinds are you baking into your H2 forecast that prevented a guidance raise?
Arvis Gen 2 Adoption Rate
With the Arvis Gen 2 system officially launched, what percentage of your ASC placements are utilizing the flexible financial models (lease/implant commit) versus upfront capital purchases, and how is that impacting near-term revenue recognition?